Episode Details

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev and Steve Cook, CEO of EMVC portfolio company DName-iT, talked with Proactive's Stephen Gunnion about advancing safety and accuracy in next-generation DNA sequencing and clinical diagnostics. The discussion focused on the rapid global growth of next-generation sequencing (NGS) in cancer testing, prenatal screening and rare disease identification, and the critical risks that emerge when processing thousands or even millions of samples at scale. Iliev reflected on lessons learned from mass PCR testing during the Covid pandemic, noting how large-scale diagnostics can expose “cracks” in systems, including false positives and false negatives with potentially serious consequences. As sequencing-based testing expands across healthcare systems, eliminating errors becomes increasingly vital. Cook explained how DName-iT addresses these risks by embedding molecular barcodes directly into the testing process. Unlike traditional safeguards such as tube labelling and laboratory protocols, which remain vulnerable to human error, DName-iT introduces patient-specific molecular sequences at the sample level. As Cook described it, the technology builds “quality assurance and safety of these kinds of tests built in at the molecular level.” The company is preparing commercial pilots, having already secured regulatory approvals and manufactured over 500 prepared samples for laboratory trials. Alongside commercialisation efforts in cancer blood testing and prenatal screening markets in the EU and US, DName-iT is also pursuing IP monetisation strategies through potential partnerships. Watch the full interview to learn how EMV Capital is supporting DName-iT’s journey toward commercialisation. For more videos like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel and enable notifications for future content. #EMVCapital #DNameiT #DNATesting #NextGenerationSequencing #NGS #CancerDiagnostics #PrenatalTesting #MolecularBarcoding #HealthcareInnovation #BiotechInvesting #ClinicalDiagnostics #MedTech